Canaccord Genuity Maintains a 'Buy' on Synageva BioPharma (GEVA); SBC-102 P1/2 Extension Data Next
Tweet Send to a FriendGet Alerts GEVA Hot Sheet
Price: $40.13 -0.4%
Rating Summary:
5 Buy, 4 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 19 | Down: 21 | New: 29
Rating Summary:
5 Buy, 4 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 19 | Down: 21 | New: 29
Trade GEVA Now!
Canaccord Genuity maintains a 'Buy' on Synageva BioPharma (NASDAQ: GEVA) price target of $60.00.
Analyst, Salveen Richter, said, "GEVA reported Q2 GAAP EPS of $(0.48), below consensus of $(0.44) and CGe of $(0.43), primarily driven by higher-than-expected operating expense ($10.2M vs. CGe of $8.9M). SBC-102, an enzyme replacement therapy (ERT) for LAL deficiency (LALD), should enter a pivotal, randomized, placebo-controlled trial in late-2012/early-2013, with additional P2 data presented at two medical meetings in H2 (SSIEM and likely AASLD). In addition, the company recently initiated a patient registry. GEVA is also developing a pre-clinical ERT for MPS IIIB – we expect an update on the program in FY13. We model for peak SBC-102 sales of ~$650M in FY20, and view SBC-102 Phase 2 extension trial data at the Society for the Study of Inborn Errors in Metabolism (SSIEM) meeting in Birmingham, England (September 4-7, 2012) as the next catalyst."
For an analyst ratings summary and ratings history on Synageva BioPharma click here. For more ratings news on Synageva BioPharma click here.
Shares of Synageva BioPharma closed at $46.26 yesterday, with a 52 week range of $10.04-$50.85.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Analyst, Salveen Richter, said, "GEVA reported Q2 GAAP EPS of $(0.48), below consensus of $(0.44) and CGe of $(0.43), primarily driven by higher-than-expected operating expense ($10.2M vs. CGe of $8.9M). SBC-102, an enzyme replacement therapy (ERT) for LAL deficiency (LALD), should enter a pivotal, randomized, placebo-controlled trial in late-2012/early-2013, with additional P2 data presented at two medical meetings in H2 (SSIEM and likely AASLD). In addition, the company recently initiated a patient registry. GEVA is also developing a pre-clinical ERT for MPS IIIB – we expect an update on the program in FY13. We model for peak SBC-102 sales of ~$650M in FY20, and view SBC-102 Phase 2 extension trial data at the Society for the Study of Inborn Errors in Metabolism (SSIEM) meeting in Birmingham, England (September 4-7, 2012) as the next catalyst."
For an analyst ratings summary and ratings history on Synageva BioPharma click here. For more ratings news on Synageva BioPharma click here.
Shares of Synageva BioPharma closed at $46.26 yesterday, with a 52 week range of $10.04-$50.85.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- KeyBank Upgrades MDC Holdings (MDC); Cuts PulteGroup (PHM) & Ryland Group (RYL)
- Toll Bros. (TOL) Q2 Solid but Not Much Better Than Peers
- Topeka Capital Starts Spansion (CODE) at Buy
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS ViewRelated Entities
Canaccord Genuity
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
